Synthesis and biological activities of hapalosin derivatives with modification at the C12 position

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 2, 2000, Pages 101-103

  Kashihara, Nobuki ^a   To E, Sakino ^a   Nakamura, Kensuke ^b   Umezawa, Kazuo ^a   Yamamura, Shosuke ^a   Nishiyama, Shigeru ^a  

^a KEIO UNIVERSITY   (Japan)

^b Inst of Medicinal Molecular Design   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPEPTIDE; HAPALOSIN DERIVATIVE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE;

ARTICLE; BLUE GREEN ALGA; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; DRUG ISOLATION; DRUG STRUCTURE; DRUG SYNTHESIS; FIBROSARCOMA; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CANCER; STEREOCHEMISTRY;

ALGAE; CHLOROPHYTA; CYANOBACTERIA;

EID: 0034677147     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00647-2     Document Type: Article

References (27)

1. Stratmann K., Burgoyne D.L., Moore R., Patterson M.L. J. Org. Chem. 59:1994;7219-7226.
2. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Cancer Res. 41:1981;1967-1972.
3. Rogan A.M., Hamilton T.C., Young R.C., Klecker R.W.Jr., Ozols R.F. Science. 224:1984;994-996.
4. Broxterman H.J., Kuiper C.M., Schuurhuis G.J., Tsuruo T., Pinedo H.M., Lankelma J. Biochem. Pharm. 37:1988;2389-2393.
5. Simon S.M., Schinller M. Proc. Natl. Acad. Sci. USA. 91:1994;3497-3504.
6. 50=5∼15 μg), see ref 1.
7. Dinh T.Q., Armstrong R.W. J. Org. Chem. 60:1995;8118-8119.
8. Ghosh A.K., Liu W., Xu L., Chen Z. Angew. Chem., Int. Ed. Engl. 35:1996;74-76.
9. Dinh T.Q., Du X., Armstrong R.W. J. Org. Chem. 61:1996;6606-6616.
10. Wagner B., Beugelmans R., Zhu J. Tetrahedron Lett. 37:1996;6557-6560.
11. Dinh T.Q., Smith C.D., Armstrong R.W. J. Org. Chem. 62:1997;790-791.
12. Dinh T.Q., Du X., Smith C.D., Armstrong R.W. J. Org. Chem. 62:1997;6773-6783.
13. Dinh T.Q., Smith C.D., Du X., Armstrong R.W. J. Med. Chem. 41:1998;981-987.
14. Wagner B., Gonzalez G.I., Dau M.E.T.H., Zhu J. Bioorg. Med. Chem. 7:1999;737-747.
15. O'Connell C., Salvato K.A., Meng Z., Littlefield B.A., Schwartz C.E. Bioorg. Med. Chem. Lett. 9:1999;1541-1546.
16. Pais G.C.G., Maier M.E. J. Org. Chem. 64:1999;4551-4554.
17. Haddad, M.; Botuha, C.; Larcheveque, M. SYNLETT 1999, 703-704.
18. Ohmori K., Okuno T., Nishiyama S., Yamamura S. Tetrahedron Lett. 37:1996;3467-3470.
19. Okuno T., Ohmori K., Nishiyama S., Yamamura S., Nakamura K., Houk K.N., Okamoto K. Tetrahedron. 52:1996;14723-14734.
20. It was anticipated that alkyl groups such as ethyl or propyl, introduced at the N-position would conduct the cis-peptide geometry, according to computational calculations. However, coupling of the corresponding alkylated amino group, or insertion of alkyl groups to the peptide moiety were unsuccessful, owing to low reactivities.
21. 22-24
22. Scheibler H., Wheeler A.S. Chem. Ber. 44:1911;2684-2690.
23. Abderhalden E., Weil A.Z. Physiol. Chem. 84:1913;39-59.
24. Mori K. Tetrahedron. 32:1976;1101-1106.
25. 18,19
26. Low cytotoxicities of 5a-5e were determined.
27. During preparation of this paper, this sample was reported: see ref 15.